Spondyloarthritis & psoriatic arthritis
Whole body-MRI identifies widespread, low intensity inflammation in peripheral joints, and axial involvement in a third of patients with early, treatment-naïve, active PsA: data from the GOLMePsA clinical trial
Authors' conclusion
In this exploratory analysis, WB-MRI identified widespread although low intensity inflammation in peripheral joints and enthesis with improvements seen at 24 and 36 weeks and no meaningful differences between treatment arms. Axial abnormalities were seen in one third of patients at baseline.
Study context
- Population
- Newly diagnosed, treatment-naïve patients with early, active PsA
- Participants
- 31 participants93 paired scans
- Comparison
- MTX plus golimumab and steroids vs MTX plus steroids
Methodological detailsexploratory analysis, whole body-MRI substudy
- Exploratory analysis
- Whole body-MRI substudy
Primary result
As reported in the abstract
Peripheral tissue inflammation, median MRI-WIPE score
37
SIJ inflammation (SPARCC score ≥2)
25.8%
10/31
Spine inflammation (SPARCC score ≥2)
32.3%
10/31
Further findings
| Outcome | GOLMTX | PBOMTX |
|---|---|---|
| Median MRI-WIPE delta (difference between time points) · week 24 and week 36Exploratory analysis | −10 | −6 |
| Week 36 | −7 | −9 |
- Median MRI-WIPE delta (difference between time points): value = week 24
Median MRI-WIPE delta (difference between time points) · week 24 and week 36
- No differences between the treatment groups were observed
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →